Evox Therapeutics

Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies for rare, genetically driven neurodegenerative diseases.

Its proprietary platform uses engineered exosomes to deliver CRISPR-based gene editors across the blood-brain barrier, enabling targeted genetic intervention in the central nervous system.

Lead programmes target the MSH3 gene in Huntington's disease and the ATXN2 gene in amyotrophic lateral sclerosis and spinocerebellar ataxia type 2, with additional programmes in Rett syndrome.